SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pagano L, Pulsoni A, Tosti ME, et al. Clinical and biological features of acute myeloid leukemia occurring as a second malignancy: GIMEMA archive of adult acute leukemia. Br J Haematol. 2001; 112: 109-117.
  • 2
    Smith SM, LeBeau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003; 102: 43-52.
  • 3
    Pullarkat V, Slovak ML, Dagis A, et al. Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: durable remissions after hematopoietic stem cell transplantation. Ann Oncol. 2009; 20: 2000-2006.
  • 4
    Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999; 340: 351-357.
  • 5
    McLauglin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone and dexamethasone (FND) plus rituximab and interferon alpha. Blood. 2005; 105: 4573-4575.
  • 6
    Pagano L, Pulsoni A, Mele L, Leone G. Clinical and epidemiological features of acute lymphoblastic leukemia following a previous malignancy. Leuk Lymphoma. 2000; 39: 465-475.
  • 7
    Ishizawa S, Slovak ML, Popplewell L, et al. High frequency of pro-B acute lymphoblastic leukemia in adults with secondary leukemia with 11q23 abnormalities. Leukemia. 2003; 17: 1091-1095.
  • 8
    Chen W, Wang E, Lu Y, Gaal KK, Huang Q. Therapy-related acute lymphoblastic leukemia without 11q23 abnormality. Am J Clin Pathol. 2010; 133: 75-82.
  • 9
    Chang H, Yeung J, Brandwein J, Yi Q-L: CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. Leukemia Res. 2007; 31: 157-162.
  • 10
    Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108: 28-37.
  • 11
    Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008; 112: 3330-3338.
  • 12
    Storring JM, Minden MD, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukemia (ALL) with a modified pediatric regimen. Br J Haematol. 2009; 146: 76-85.
  • 13
    Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004; 101: 2788-2801.
  • 14
    Shivakumar R, Tan W, Wilding GE, Wang ES, Wetzler M. Biologic features and treatment outcome of secondary acute lymphoblastic leukemia—a review of 101 cases. Ann Oncol. 2008; 19: 1634-1638.
  • 15
    Pagano L, Pulsoni A, Tosti ME, et al. Acute leukemia following a previous malignancy: do acute lymphoid leukemia and acute myeloid leukemia have common risk factors? Hematol J. 2000; 1: 329-332.
  • 16
    Vey N, Thomas X, Picard C, et al. Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia. 2006; 20: 2155-2161.